Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Amplyx doses first patient in Phase II APX001 study

Microscopic image of candida albicans ATCC 10231. Credit: Y tambe.



  • Amplyx Pharmaceuticals

Go Top